Moving geroscience from the bench to clinical care and health policy

Перенос геронауки из лаборатории в клиническую практику и политику здравоохранения
George A. Kuchel, Eric M. Verdin, Avshalom Caspi, Gordon J. Lithgow, Felipe Sierra, Terrie E. Moffitt, Laura Haynes, S. Jay Olshansky, Daniel P. Perry, Richard H. Fortinsky
2021-06-19

Geroscience Hypothesisbiological agingclinical translationgerosciencehealth policy
Geriatricians and others must embrace the emerging field of geroscience. Until recently geroscience research was pursued in laboratory animals, but now this field requires specialized expertise in the care of vulnerable older patients with multiple chronic diseases and geriatric syndromes, the population likely to benefit the most from emerging therapies. While chronological aging measures the inevitable passage of clock time that occurs equally for everyone, biological aging varies among individuals, and importantly, it is modifiable. Advances in our understanding of biological aging, the discovery of strategies for modifying its rate, and an appreciation of aging as a shared risk factor for chronic diseases have jointly led to the Geroscience Hypothesis. This hypothesis states that interventions modifying aging biology can slow its progression-resulting in the delay or prevention of the onset of multiple diseases and disorders. Here we wish to report on the Third Geroscience Summit held at National Institutes of Health on November 4-5, 2019, which highlighted the importance of engaging other disciplines including clinicians. Involvement by scientists with expertise in clinical trials, health outcomes research, behavioral and social sciences, health policy, and economics is urgently needed to translate geroscience discoveries from the bench to clinical care and health policy. Adding to the urgency of broadening this geroscience coalition is the emergence of biological aging as one the most important modifiable factors of COVID-19, combined with the inability of our society to once again recognize and confront aging as a priority and opportunity when facing these types of public health emergencies.
1
Biological aging varies between individuals and is modifiable, unlike chronological aging, making it a potential target for intervention.
2
Geroscience must expand beyond laboratory animal research to include expertise in caring for vulnerable older adults with multimorbidity and geriatric syndromes.
3
The Geroscience Hypothesis proposes that modifying aging biology can delay or prevent multiple age-related diseases and disorders simultaneously.
4
The emergence of biological aging as a major modifiable factor in COVID-19 underscores the need to prioritize geroscience in public-health preparedness and policy.
5
Translating geroscience into clinical care and health policy urgently requires collaboration among clinicians, clinical-trial researchers, outcomes scientists, behavioral and social scientists, policymakers, and economists.

biological aging in vulnerable older adults with multiple chronic diseases and geriatric syndromes

modification of aging biology to delay or prevent multiple diseases and disorders, and translation of geroscience discoveries into clinical care and health policy

Publication Details
Publication Date
2021-06-19
Journal
Publisher
ISSN
Cited by
95
Access Type
Author Information
Authors
George A. Kuchel
Eric M. Verdin
Avshalom Caspi
Gordon J. Lithgow
Felipe Sierra
Terrie E. Moffitt
Laura Haynes
S. Jay Olshansky
Daniel P. Perry
Richard H. Fortinsky
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%